Biocon's Q2 preview highlights strong biosimilar growth, while generics face challenges amid mixed sector performance ahead of November 11 results.
Analysts remain bullish on Vedanta Ltd, citing strong earnings potential and strategic positioning amid a recovering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback